| PSP Free Members, Coming off the heels of a solid week... ...I've got us a hot Pharmaceutical stock that I believe is about to see a breakout! This company has been building steady momentum over the last 2 weeks, and recently the stock has pulled back to give us a perfect entry point. I believe this stock has the potential to break it's 52-week high, and if it does, it could send the stock into an entirely new price level! The company recently secured 9 distribution partners in the European Union, and will be starting a massive sales push, rolling out their products to 1,200 pharmacies, and 150 hospitals by the 3rd quarter of 2011. Demand for this company's products is expected to nearly DOUBLE by 2015! I believe this stock could be one of the top performing stocks in its sector, in the very near term! -James +++++++++++++++++++++++++++++++++++++++++++++++++++++++ NEW PICK Genmed Holding Corp (OTCBB) GENM Currently Trading: $0.46 PSP Members, I've got us a Pharmaceutical pick that has been picking up momentum the past couple weeks as new distribution was announced, along with a huge 2011 sales push that's right around the corner. GENM is a U.S. & Dutch based company engaged in the sale and distribution of low cost generic-drugs, primarily a generic form of Tylenol. The Company expects purchase orders and initial shipments to begin within the first quarter of 2011. GENM also just announced a major 5-year distribution agreement to distribute their products throughout the European Union! GENM's products will be rolled out to over 1,200 pharmacies, and 150 hospitals by the 3rd quarter of 2011! Generic Drugs? Really? Yes! The generic drug market is experiencing unbelievable growth right now due to rising health care costs. The generic drug market was estimated at $89 Billion in 2009 and is expected to grow to $135 - 150 Billion by 2015!
In fact, Goldman-Sachs Global Investment Research estimates that big names in the innovator drug market may lose up to 49% of their business to generic pharmaceutical companies by 2015! Take a guess as to how much acetaminophen is consumed worldwide? Would you believe over 120,000 TONS per year! With a pill weighing virtually nothing that is a staggering number. The top ten global manufacturers and distributors of generic drugs only account for 66% of the market. This means GENM could become a strong potential acquisition target! GENM Future Growth: The open market condition of the industry not being locked down by a few mega-corporations leaves room for GENM to both grow into the gap in the market, as well as become a potential acquisition target. GENM Government Savings: While not only growing faster in terms of revenues, generics are also saving government healthcare programs and the everyday consumer money. In the United States, generic medicines have saved the American health care system more than $734 billion dollars in the last decade while in the United Kingdom generic competition saves the National Health Service (NHS) £8.6 billion per year! GENM Current News: 1/20/11 Large European Distribution Contract GENM signed a 5 Year Distribution Contract with an Irish multi-national pharmaceutical distribution company - The product will be rolled out to the distributor's network of more than 1,200 pharmacies and more than 150 hospitals starting in the 3rd quarter of 2011. Additionally, the Company announced on the 25th that the roll out would include Scotland and Northern England as well. GENM Business Strategy: GENM has several competitive advantages: - GENM has taken the necessary steps to acquire distribution licenses in Romania, Holland, the United Kingdom, United States, Germany and Ireland.
- With these licenses, GENM can initiate new distribution licenses in the rest of the world.
- GENM has the ability to sell directly to the distributor and cut out wholesalers, which offers lower production and distribution costs, and faster delivery.
- GENM's production facility adheres to the strictest worldwide standards for generic pharmaceutical production.
GENM Mission Genmed's mission is to provide and offer EMEA and FDA quality generic medicines at lower prices than the current market prices and therefore contribute to the accessibility of high quality medicines for every human being. This sounds like a great fit for Universal Healthcare coverage that exists in Europe! GENM Products: GENM has a license to market and distribute Acetaminophen (also known as Paracetamol), which is the scientific name for Tylenol, marketed and distributed by Johnson & Johnson. Genmed's market focus will take place in Europe, which accounts for 25% of acetaminophen consumption. Genmed have acquired distribution rights for NINE countries including: The Netherlands, Belgium, Luxemburg, Ireland, United Kingdom, Germany, France, Scotland, & Northern England GENM Executive Highlights: An experienced management team and board, who have considerable and highly relevant experience in product development, registration, sales, marketing, distribution, operations, and financial administration, lead GENM. Erwin R. Bouwens -CEO In 2000, Mr. Bouwens began an occupational health care services company (De Witte Raaf) employing 129 people with 24 occupational health doctors and working with the 50 largest companies in Holland. He has spent the last three years securing a relationship with Atabay, developing the current management team and making inroads with major distribution networks to disperse generic drugs. GENM Technical Indicators: GENM has an estimated market capital of roughly $75,000,000, with the stock currently trading around $0.46 cents. This is a very solid number for small caps. It means that there is an actual market backing up the Company. IMPORTANT! With an average 175,000 volume over the past 10 days, GENM has seen a stock increase from $0.37 cents to a HIGH of $0.54 cents last Monday. An impressive 46% gain in a short period! With a very healthy entry point of 46 cents, I think there is potential here for another strong run! GENM looks set for another run back to it's 52-week high of $0.55 cents, and could even past it as positive momentum and investor interest drives the stock up. It looks as though earlier investors cashed out profits, but GENM has shown little resistance at similar price levels and has maintained strong bid support. I also suspect that if the bulls push the stock up, shorts will need to cover, presenting even more profit opportunities! Lets get ready to book potential profits starting Monday! I recommend taking a look at GENM this evening and tomorrow morning. The stock has the potential to do very well in the short-term, with volume and interest surging. Happy Trading, -James
Disclaimer: (Please Read)
Never invest in any stock featured on the PennyStockProphet.com website or email alerts unless you can afford to lose your entire investment. Many of the stocks featured are highly speculative. PennyStockProphet.com has been compensated Forty Thousand Dollars by a third party for a one week advertising contract regarding Genmed Holdings Corp (GENM.OB) The third party may have shares and may sell their shares at anytime. It is important to understand that it is possible that this could have a negative effect on the stock price. Neither James Connelly nor PennyStockProphet.com employees are registered as investment advisors, financial analysts, brokers, or dealers in any jurisdiction whatsoever. Your use of the PennyStockProphet.com website, email alerts, and all other services means that you agree to hold PennyStockProphet.com, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may suffer. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation for the purchase or sale of any securities. The information provided is obtained from sources deemed reliable, but PennyStockProphet.com does not guarantee in any way the timeliness, sequence, accuracy, adequacy, or completeness of such information made regarding stocks discussed on PennyStockProphet.com or in email alerts. The owner, publisher, editor and their associates are not responsible for errors and omissions. You understand and agree that at the time of any transaction you make James Connelly, PennyStockProphet.com employees, PennyStockProphet.com affiliates, and friends and family of James Connelly may have a position in such securities. The position may have been acquired prior to the publication of any website information or email alert. You should also be aware that the aforementioned parties do have the right to sell their positions at any time without further notification. Any opinions expressed are subject to change without notice. PennyStockProphet.com encourages readers and investors to supplement the
information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or persons affiliated with or associated with such companies; or is available from public sources. Read our full disclaimer at:
http://pennystockprophet.com/Disclaimer.html
| 
No comments:
Post a Comment